H.C. Wainwright analyst Vernon Bernardino reiterated a Buy rating on Gamida Cell (GMDA – Research Report) on February 10 and set a price target of $22.00. The company’s shares closed last Monday at $3.46, close to its 52-week low of $2.10.
According to TipRanks.com, Bernardino is a 5-star analyst with an average return of 27.3% and a 35.3% success rate. Bernardino covers the Healthcare sector, focusing on stocks such as Eledon Pharmaceuticals, Citius Pharmaceuticals, and Aridis Pharmaceuticals.
Currently, the analyst consensus on Gamida Cell is a Strong Buy with an average price target of $15.40, representing a 303.1% upside. In a report issued on February 1, JMP Securities also reiterated a Buy rating on the stock with a $17.00 price target.
Based on Gamida Cell’s latest earnings release for the quarter ending September 30, the company reported a quarterly GAAP net loss of $19.63 million. In comparison, last year the company had a GAAP net loss of $14.75 million.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Gamida Cell Ltd. is a clinical stage biopharmaceutical company engaging in the development of cell therapies to cure blood cancer and rare serious hematologic diseases. The company was founded by Tony Peled and Menashe Levy in 1998 and is headquartered in Jerusalem, Israel.
Read More on GMDA:
- H.C. Wainwright Thinks MEI Pharma’s Stock is Going to Recover
- H.C. Wainwright Reiterates Their Buy Rating on Solitario Exploration & Royalty (XPL)
- Scorpio Tankers (STNG) Gets a Buy Rating from H.C. Wainwright
- Wall Street Analysts Are Bullish on Top Healthcare Picks
- Berenberg Bank Thinks Seagen’s Stock is Going to Recover